Observational Study That Will Evaluate Treatment Patterns in the Management of Hypertension in the Public Primary Care System

ConditionHypertension
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAstraZeneca

About this trial

This is a retrospective observational cohort study based on secondary use of routinely collected electronic health data. The design was selected to enable population-level characterisation of treatment patterns and clinical inertia (both diagnostic and therapeutic) in the management of hypertension across diverse settings in Brazil's public primary care system (SUS).

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age ≥18 years at the time of Hypertension diagnosis

Hypertension diagnosis as retrieved from registered ICD codes or CIAP Codes (primary care codes) in the EMR , OR At least two blood pressure measurements ≥140/90 mmHg during the study period. The blood measurements should be consecutive and obtained within a 30 days period.

Continuous follow-up in the same municipality for at least 6 months after index measurement.

Availability of structured EMR data including clinical encounters, diagnoses, and prescriptions

Disqualifiers

None

Trial population

Adults registered in the e-SUS PEC system who had encounters with primary healthcare services within the study period and had blood pressure measurements recorded. We will assess data from the entire population of approximately 05 muncipalities (comprising between 100.000 and 250.000 inhabitants). The municipalities will be seleceted from a pre-screened list of 20 cities located within all Brazilian regions.

Trial design

Design model

Cohort

Time perspective

Retrospective

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Trial outcomes

Primary outcomes

1

Uncontrolled blood pressure

Proportion of patients with uncontrolled blood pressure (BP ≥ 140/90 mmHg) who did not receive treatment intensification within 3 months of a recorded elevated BP.

Time frame
through study completion, an average of 1 year

Secondary outcomes

1

Antihypertensive treatment

Proportions receiving monotherapy vs. combination therapy; distribution by pharmacologic class.

Time frame
through study completion, an average of 1 year
2

Risk stratification

Likelihood of treatment escalation stratified by low/moderate vs. high/very high CV risk.

Time frame
through study completion, an average of 1 year

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.